-

VectorBuilder Wins BioIndustrial Innovation of the Year Award

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition underscores VectorBuilder’s significant contributions to gene delivery technology through its Vector Design Studio, which has revolutionized the way researchers worldwide create and order custom gene delivery vectors.

Now in its fourth year, the annual BioTech Breakthrough Awards recognize the world’s best life sciences and biotechnology companies, products, and services. VectorBuilder’s platform was selected for its efficiency, user-friendliness, and ability to accelerate research timelines. The Vector Design Studio has become an indispensable tool for over 300,000 life sciences labs globally, meeting the demand for a faster, more reliable vector design and construction solution.

“Winning this reward reflects our continued commitment to accelerating the pace of gene therapy research through advanced technologies and custom-built solutions transforming how diseases are treated,” said Bruce Lahn, Chief Scientist at VectorBuilder. “Our platform’s ability to reduce vector creation timelines from months to just a few weeks allows researchers to focus on what truly matters: advancing knowledge and developing innovative research and therapies.”

Traditionally, labs have relied on in-house cloning for vector creation, a process that can be slow, costly, and inconsistent. VectorBuilder’s Vector Design Studio changes this by offering an intuitive, Web-based platform that allows even novice researchers to design and order custom vectors with just a few clicks. The platform includes access to an extensive library of over 1,100 vector backbones and more than 400,000 vector components, providing tailored vector solutions with unmatched speed and precision.

The platform has achieved widespread success and adoption. To this end, it’s been used to design over one million vectors that have been cited in more than 5,000 publications, including journals like ‘Science,’ ‘Nature,’ and ‘Cell.’

“The Vector Design Studio merges cutting-edge information technology with synthetic and molecular biology to provide a scalable solution for labs of all sizes,” said Lahn. “By automating the process from demand analysis to vector optimization and delivery, we offer a cost-effective model that helps labs accelerate their research timelines and lower labor expenses. This award inspires us to continue pushing the boundaries of what’s possible in gene delivery.”

Beyond its technical innovation, VectorBuilder’s platform also delivers a significant financial impact. With more than 80% of custom vectors made from ready-made elements, VectorBuilder’s streamlined approach allows for large-scale production, enabling labs to complete projects faster and more affordably. The Vector Design Studio has pioneered a new era of large-scale gene vector production, which has the potential to accelerate life sciences research by up to 20%, according to leading investment firm Legend Capital.

VectorBuilder is a global CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) providing comprehensive, end-to-end gene delivery solutions, including custom vector design, plasmid production, and viral vector manufacturing. With a strong foundation in GMP manufacturing, VectorBuilder has earned the trust of over 4,500 academic institutions and biotech/pharmaceutical companies worldwide.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.

Contacts

More News From VectorBuilder

VectorBuilder to Present on Therapeutic Vector Design at ASGCT 2026

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11 to 15 in Boston, Massachusetts. As gene and cell therapies move closer to clinical and commercial scale, the industry is placing greater scrutiny on how early vector design decisions influence manufacturability, consistency, and downstream outcomes. These considerations are expec...

VectorBuilder Secures European Patent for MiniVec™, a Plasmid Backbone Advancing Safety and Manufacturability in Genetic Medicine

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology and reinforcing its position at the forefront of gene delivery innovation. MiniVec™ was developed to remove constraints that have historically limited plasmid safety, scalability, and regulatory acceptance. By minimizing ba...

VectorBuilder to Present on Advancing AAV-Based Therapies at ARVO 2026

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado, from May 3 to 7. As AAV-based gene therapies continue to gain traction in ophthalmology, attention is shifting toward the underlying factors that influence consistency, durability, and clinical performance. Variability in vector design and production remains...
Back to Newsroom